Cure8 research brief
A subcutaneous option for infliximab could simplify maintenance therapy, reduce infusion visits, and change how drug levels and accompanying immunomodulators are managed — issues many people with IBD and their clinicians care about.
Adults with IBD considering or receiving infliximab (including those switching from IV to SC), clinicians managing biologic therapy, researchers studying biologic delivery methods, and pregnant patients on infliximab.
The article reports that subcutaneous infliximab was developed to reduce peak-to-trough variability seen with intravenous dosing and to address immunogenicity linked to low troughs.
It synthesizes pivotal phase 3 data and switching studies, and discusses recalibrating therapeutic drug monitoring and possible immunomodulator de-escalation guided by steady-state drug levels.
The review highlights special populations considered in emerging evidence, such as people with obesity, perianal disease, pediatric IBD, and pregnancy, and it frames subcutaneous infliximab as likely to become the default maintenance route for many patients while IV remains important for acute/high-burden induction.
This record is an expert narrative review (abstract-level content available). It synthesizes phase 3 trials, randomized comparisons, and real-world cohorts but does not replace clinical guidelines or regulatory labeling. Proposed shifts to routine practice are expert expectations rather than finalized standards.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study suggests that cumulative infliximab exposure over time (AUC) — not just trough levels — may predict infection risk in people with IBD. That could affect how clinicians use therapeutic drug monitoring to...
Proactive TDM of infliximab was associated with high 1‑ and 2‑year durability in this pediatric Crohn's cohort, and the study flags clinical factors that may predict need to switch biologics. This could be relevant when...
Infliximab dosing can be hard to personalize. This study shows that selecting pharmacokinetic models based on IBD type and severity can improve how well drug levels are predicted, which could help tailor dosing for...
